CAR - T Cell therapy, CAR T Therapy, CAR T-Cell, chimeric agent
A Deep Dive into CAR T Cell Therapy: How Does It Work?
Discover the science behind CAR T Cell therapy treatment in India! Explore how this revolutionary treatment transforms your immune cells into cancer fighters. Read our blog now to learn more about this miraculous therapy and how ..
B-cell lymphoma, DLBCL, POLARIX, Polatuzumab, polatuzumab vedotin
Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
May 2023: For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Inde..
BMT, Gamida Cell Ltd, hematologic malignancies, Omidubicel
Omidubicel is approved by USFDA to reduce time to neutrophil recovery and infection in patients with hematologic malignancies
May 2023: Omidubicel-onlv (Omisirge, Gamida Cell Ltd.) was approved by the Food and Drug Administration for use in adult and paediatric patients (12 years of age and older) with hematologic malignancies who are scheduled to recei..
Did I Ever Tell You This, Jurassic Park, Jurassic World Dominion, Sam Neill
Sam Neill, “Jurassic Park” actor, has been diagnosed with blood cancer
March 2023: The first chapter of Sam Neill's memoir would be a tremendous shock to someone who had no prior knowledge of it. It starts out funny enough: a great yarn about his daughter Elena being questioned about her father's jo..
CAR T Cell therapy trials, multiple myeloma trials
Clinical trial on CAR-T Cell therapy for patients with BCMA/TACI-positive relapsed and/or refractory multiple myeloma
Brief Summary: A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma Detailed Description: This is a single arm, open-label, si..
AZA-JMML-001, Celgene Corporation, juvenile myelomonocytic leukemia, NCT02447666, Vidaza
Azacitidine is approved by FDA for newly diagnosed juvenile myelomonocytic leukemia
June 2022: The FDA has approved the drug azacitidine (Vidaza, Celgene Corp.) for children with newly diagnosed juvenile myelomonocytic leukaemia (JMML).The pharmacokinetics, pharmacodynamics, safety, and activity of azacitidine p..
BCMA, CARVYKTI, ciltacabtagene autoleucel, immunomodulatory agent, Janssen Biotech, proteasome inhibitor
Ciltacabtagene autoleucel is approved for relapsed or refractory multiple myeloma
March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, the Food and Drug Administration has approved ciltacabtagene au..
Study suggest CAR T-Cell therapy effective as first line treatment for high risk large B-cell lymphoma
March 2022: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), is a safe and effective first-line therapy for patients wit..
Burkitt lymphoma, Burkitt-like lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications
March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma..
Amgen, carfilzomib, Darzalex Faspro, dexamethasone, Janssen Biotech, Kyprolis, multiple myeloma
Darzalex faspro, kyprolis, and dexamethasone is approved by FDA for multiple myeloma
March 2022: Daratumumab + hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen, Inc.) plus dexamethasone have been approved by the Food and Drug Administration for adult patients with relap..